Sagimet Biosciences Inc. (SGMT) stock

SGMTNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/30

$10.22−0.71 (-6.50%)

Close on Nov 13, 2026Market cap $635.26MP/E –Yield –

Sagimet Biosciences total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Sagimet Biosciences has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

See a number that looks wrong?